Traduction de «mortality and cardiovascular morbidity » (Néerlandais → Français) :

29. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
28. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.

3 Article du Journal de l’Association médicale canadienne (JAMC), “ Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term”, [http ...]
3 Article du Journal de l’Association médicale canadienne (JAMC), “Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term”, [http ...]

hypertension alone: 24.8% vs. 13.8%, p < 0.001 Page and 4 [516b] 12,954 singleton Fetal mortality In third trimester: CH Christianso pregnancies in and increase in fetal deaths n, California, USA morbidity and morbidity above 95 1976 from 1959 to mmHg 1967
Middle trimester, stillbirth rate: In white women (n = 10,074): – without proteinuria and < 90mmHg = 8.4 – without proteinuria and º 90 mmHg = 14.8

Naar K. Dickstein et al.: Effects of losartan and captopril on mortality and morbidity in highrisk patients after acute myocardial infarction: the OPTIMAAL randomised trial.
D’après K. Dickstein et al.: Effects of losartan and captopril on mortality and morbidity in highrisk patients after acute myocardial infarction: the OPTIMAAL randomised trial.

Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis Morbidity and Mortality Weekly Report Recommendations and Reports MMWR 2005; 54(RR9).1-17.
Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis Morbidity and Mortality Weekly Report Recommendations and Reports MMWR 2005 ; 54(RR9).1-17.

- Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR).
− Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report (MMWR).

Behandeling met candesartan cilexetil vermindert mortaliteit, vermindert hospitalisatie ten gevolge van hartfalen en verbetert de symptomen bij patiënten met een verminderde systolische linkerventrikelfunctie zoals werd aangetoond in het ‘Candesartan in Heartfailure – Assessment of Reduction in Mortality and morbidity’ (CHARM) programma.
Le traitement par candésartan cilexetil réduit la mortalité et les hospitalisations liées à l'insuffisance cardiaque et améliore les symptômes des patients présentant une dysfonction systolique ventriculaire gauche, comme démontré dans le programme d'études CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity).

They cause a net increase in the rate of nosocomial infections 4 , significant and increased morbidity 5,6 , mortality 6,7 and cost 8,9 , are more difficult to treat and respond less well to therapy.
Elles causent une nette augmentation du taux d’infections nosocomiales 4 , une morbidité 5,6 , une mortalité 6,7 et un coût 8,9 importants et accrus, sont plus difficiles à traiter et répondent moins bien à la thérapie.

with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European prospective Investigation into Cancer and nutrition study (EPIC-Heidelberg).
myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European prospective Investigation into Cancer and nutrition study (EPIC-Heidelberg).

Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
DOI : 10.1002/ 14651858.CD008143.pub2. Boussageon R, Bejan-Angoulvant T, Saadatian M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.